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Abstract
Objectives:	To	aid	the	development	of	treatment	for	cognitive	impairment	in	bipolar	
disorder,	the	International	Society	for	Bipolar	Disorders	(ISBD)	convened	a	task	force	
to	create	a	consensus-	based	guidance	paper	for	the	methodology	and	design	of	cogni-
tion	trials	in	bipolar	disorder.
Methods:	The	task	force	was	launched	in	September	2016,	consisting	of	18	interna-
tional	experts	from	nine	countries.	A	series	of	methodological	issues	were	identified	
based	 on	 literature	 review	 and	 expert	 opinion.	 The	 issues	were	 discussed	 and	 ex-
panded	upon	in	an	initial	face-	to-	face	meeting,	telephone	conference	call	and	email	
exchanges.	Based	upon	these	exchanges,	recommendations	were	achieved.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	in	any	
medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
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1  | INTRODUCTION
There	 is	 a	 pressing	 need	 for	 treatments	 targeting	 cognitive	 impair-
ments	in	bipolar	disorder	to	enhance	functional	recovery	and	reduce	
societal	costs.1	Specifically,	cognitive	impairments	in	sustained	atten-
tion,	verbal	memory	and	executive	function	often	persist	after	clinical	
remission	from	mood	episodes	2,3	and	may	be	 influenced	further	by	
mood-	stabilizing	and	antipsychotic	treatments.4,5	Emerging	evidence	
points	to	cognitive	heterogeneity	in	the	remitted	phase	of	bipolar	dis-
order,	with	12%-	40%	of	patients	displaying	global	cognitive	deficits,	
29%-	40%	 showing	 selective	 decline	 in	 attention	 and	 psychomotor	
speed,	 and	 32%-	48%	 being	 relatively	 cognitively	 intact.6-8	 Notably,	
the	 subgroups	 with	 neurocognitive	 impairments	 present	 reduced	
functional	capacity,	more	stress	and	poorer	quality	of	life	than	patients	
who	 are	 cognitively	 intact,	 despite	 similar	 degrees	 of	 subsyndromal	
mood	symptoms.7,8	This	highlights	 a	need	 to	 target	 cognition	 treat-
ments	specifically	to	the	cognitively	impaired	subgroups.
There	is,	however,	a	lack	of	clinically	available	effective	treatments	
for	cognitive	impairments	in	bipolar	disorder.	This	is	partially	a	result	
of	major	methodological	challenges	in	this	relatively	new	field,	as	high-
lighted	in	a	previous	systematic	review	of	clinical	studies	of	candidate	
cognition	treatments	in	bipolar	disorder1	and	a	recent	expert	opinion	
paper.9	In	particular,	the	review	noted	that	the	majority	of	trials	used	
no	systematic	pre-	screening	for	cognitive	impairment.	Further,	criteria	
used	for	selecting	trial	participants,	tests	used	for	assessing	treatment	
efficacy	on	cognition,	 allowance	of	non-	study	medications,	 and	 sta-
tistical	procedures	differed	between	the	studies.1,9	Such	broad	meth-
odological	 discrepancies	 provide	 the	 impetus	 for	 greater	 consensus	
in	the	field,	on	the	design	and	methodology	of	cognition	trials	 in	bi-
polar	 disorder,	 to	 optimize	 the	 chances	 of	 demonstrating	 treatment	
efficacy	on	 cognition	and	 to	 aid	 comparability	 across	 trials.	 In	 addi-
tion,	 a	 key	 challenge	 in	 the	 clinical	management	of	 bipolar	 disorder	
is	the	absence	of	recommendations	for	physicians	on	how	to	assess	
and	manage	cognitive	impairments	in	their	patients.	The	International	
Society	for	Bipolar	Disorders	(ISBD)	therefore	convened	an	expert	task	
force	under	the	lead	of	Dr	Miskowiak	with	the	aim	of	developing	(i)	a	
consensus-	based	guidance	paper	for	the	methodology	and	design	of	
cognition	trials	in	bipolar	disorder	for	pharmacological	as	well	as	non-	
pharmacological	 interventions,	 (ii)	 a	 clinical	 recommendations	 paper	
for	physicians	on	how	to	address	cognitive	 impairments	 in	 their	pa-
tients,	and	(iii)	an	educational	patient	booklet	with	information	about	
cognitive	impairments	and	pragmatic	strategies	for	compensating	for	
these	in	daily	life.
This	specific	paper	addresses	goal	(i).	As	the	field	is	at	an	early	stage	
in	its	development,	defining	a	set	of	fixed	guidelines	for	cognition	tri-
als	would	 be	premature;	 the	 aim	of	 the	 present	 paper	 is	 instead	 to	
provide	consensus-	based	guidance	and	recommendations	from	inter-
national	experts	in	the	field	that	can	support	decisions	regarding	the	
methodology	and	design	of	future	cognition	trials	in	bipolar	disorder.	
While	the	task	force	recommendations	are	primarily	intended	for	ran-
domized	controlled	cognition	trials,	the	principles	can	also	be	applied	
to	naturalistic	or	quasi-	experimental	studies.	These	consensus-	based	
methodological	recommendations	build	on	insights	from	a	recent	sys-
tematic	review	of	trials	targeting	cognition	in	bipolar	disorder1 and an 
expert	opinion	paper,9	which	were	reviewed,	discussed	and	expanded	
on	by	members	of	this	ISBD	task	force.
Results:	Key	methodological	challenges	are:	 lack	of	consensus	on	how	to	screen	for	
entry	into	cognitive	treatment	trials,	define	cognitive	impairment,	track	efficacy,	assess	
functional	 implications,	 and	manage	mood	 symptoms	 and	 concomitant	 medication.	
Task	force	recommendations	are	to:	(i)	enrich	trials	with	objectively	measured	cogni-
tively	impaired	patients;	(ii)	generally	select	a	broad	cognitive	composite	score	as	the	
primary	outcome	and	a	functional	measure	as	a	key	secondary	outcome;	and	(iii)	 in-
clude	remitted	or	partly	remitted	patients.	It	is	strongly	encouraged	that	trials	exclude	
patients	with	current	substance	or	alcohol	use	disorders,	neurological	disease	or	unsta-
ble	medical	illness,	and	keep	non-	study	medications	stable.	Additional	methodological	
considerations	 include	neuroimaging	 assessments,	 targeting	of	 treatments	 to	 illness	
stage	and	using	a	multimodal	approach.
Conclusions:	This	ISBD	task	force	guidance	paper	provides	the	first	consensus-	based	
recommendations	for	cognition	trials	in	bipolar	disorder.	Adherence	to	these	recom-
mendations	will	likely	improve	the	sensitivity	in	detecting	treatment	efficacy	in	future	
trials	and	increase	comparability	between	studies.
K E Y W O R D S
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2  | MATERIALS AND METHODS
2.1 | The ISBD Targeting Cognition Task Force
The	 ISBD	 Targeting	 Cognition	 Task	 Force	 was	 initiated	 by	 Drs	
Miskowiak,	 Kessing,	 and	 Vieta	 and	 consisted	 of	 18	 international	
experts	 in	 cognition	 in	 affective	disorders	 from	 the	 following	nine	
countries	(in	alphabetical	order):	Brazil,	Canada,	Colombia,	Denmark,	
Japan,	New	Zealand,	Spain,	the	UK,	and	the	USA.	The	members	of	
the	ISBD	Targeting	Cognition	Task	Force	were	selected	based	upon	
their	 expertise	 in	 cognition	 in	 bipolar	 disorder	 and	 include	 sev-
eral	members	 of	 a	 previous	 ISBD	Cognition	 Task	 Force	 led	 by	Dr	
Yatham.10
2.2 | The process of the task force
A	series	of	major	methodological	challenges	in	the	field	were	identi-
fied	from	a	recent	systematic	review	of	cognition	trials	in	bipolar	disor-
der1	and	a	methodological	expert	opinion	paper	on	the	assessment	of	
cognition	in	this	patient	group.9	An	introductory	face-	to-	face	meeting	
was	then	held	at	the	European	College	of	Neuropsychopharmacology	
(ECNP)	annual	congress	(Vienna,	September	2016),	during	which	the	
overall	 work	 timelines	 for	 accomplishing	 the	 goals	 were	 discussed,	
a	tentative	list	with	the	key	methodological	issues	in	cognition	trials	
was	reviewed	and	agreed	upon,	and	possible	solutions	to	the	issues	
were	 discussed.	 This	 was	 followed	 up	 by	 a	 telephone	 conference	
with	the	members	of	the	task	force	who	were	unable	to	attend	the	
introductory	meeting.	During	 the	call,	 the	 identified	methodological	
challenges	 and	possible	 solutions	were	 discussed	 and	 agreed	upon,	
and	additional	 challenges	were	added	 to	 the	 list.	Consensus	on	 the	
methodological	challenges	and	recommendations	with	regard	to	how	
these	 challenges	 may	 be	 tackled	 was	 reached	 through	 subsequent	
email	exchanges.	Any	differences	in	opinion	between	task	force	mem-
bers	were	resolved	in	all	cases	through	a	telephone	call	between	the	
particular	task	force	members	and	the	task	force	chair	(Dr	Miskowiak).	
The	use	of	formal	consensus	methods	such	as	the	Delphi	method	was	
deemed	unnecessary	 given	 a	 high	 degree	 of	 agreement	 among	 the	
members	of	the	task	force.
3  | RESULTS
3.1 | How can we enrich trials with cognitively 
impaired patients?
One-	third	to	half	of	patients	with	bipolar	disorder	do	not	show	clini-
cally	 relevant	 objectively	 measured	 cognitive	 impairments	 during	
remission.	A	major	reason	for	the	overall	lack	of	progress	in	develop-
ment	of	new	treatments	for	cognitive	impairment	in	bipolar	disorder	
may	have	to	do	with	the	fact	that	most	(80%)	cognition	trials	do	not	
pre-	screen	 patients	 for	 cognitive	 impairment,	 thus	 including	 a	 per-
centage	of	cognitively	intact	patients,	which	affects	signal	detection.1 
The	task	force	therefore	considers	it	critical	in	randomized	controlled	
trials	(RCTs)	to	pre-	screen	patients	for	cognitive	impairment.	This	will	
increase	statistical	power	and	thus	the	likelihood	of	signal	detection,	
minimize	 the	 risk	of	unnecessary	exposure	of	 cognitively	 intact	pa-
tients	to	novel	investigational	treatments,	reduce	treatment	develop-
ment	costs,	and	result	in	a	shorter	time	to	bring	novel	treatments	to	
patients	with	cognitive	deficits.
Among	the	20%	(n	=	23)	of	cognition	trials	in	bipolar	disorder	that	
did	 include	 pre-	screening	 for	 cognitive	 impairment,	 a	 vast	 majority	
used	subjectively	self-	reported	rather	than	objective	neuropsycholog-
ical	screening	tools.1	Since	up	to	half	of	remitted	patients	are	objec-
tively	cognitively	intact	despite	subjective	cognitive	complaints,6,7	this	
can	lead	to	enrollment	of	patients	with	little	or	no	scope	for	cognitive	
improvement	and	thus	a	high	risk	of	type	II	errors.11-13	Indeed,	recent	
evidence	 from	 several	 cognition	 trials	 suggests	 that	 patients	 with	
objectively	assessed	cognitive	 impairment	have	substantially	greater	
chances	of	achieving	treatment	efficacy	on	cognition	than	those	who	
are	 non-	impaired.11,12,14-16	 While	 subjectively	 perceived	 cognitive	
difficulties	may	also	 increase	the	 likelihood	of	 treatment	efficacy	on	
cognition,	this	association	is	weak14	and	not	consistently	observed.15 
It	 therefore	 seems	 insufficient	 to	 rely	 only	 on	 patients’	 subjectively	
reported	cognitive	difficulties,	although	these	are	arguably	important	
for	 patient	 participation	 in	 trials	 and	 for	 clinical	 meaningfulness	 of	
cognition	treatments.	Indeed,	the	correlation	between	subjective	and	
objective	measures	of	 cognition	 is	poor,17,18	 indicating	 that	 it	 is	not	
always	the	patients	with	most	subjective	complaints	who	show	great-
est	objective	deficits	and	vice	versa.	This	discrepancy	seems	to	be	in-
fluenced	by	 patients’	 clinical	 characteristics,	with	 disproportionately	
more	subjective	than	objective	cognitive	impairment	in	patients	with	
greater	subsyndromal	depression	or	mania	symptom	severity,	bipolar	
disorder	type	II	(vs	type	I),	and	greater	illness	chronicity.19
Given	the	poor	correlation	between	subjective	and	objective	cog-
nition	measures	and	some	evidence	for	greater	treatment	benefits	in	
objectively	 impaired	 patients,	 it	 seems	 reasonable	 to	 enrich	 for	 ob-
jective	cognitive	impairment	in	future	trials	to	achieve	more	positive	
outcomes	of	RCTs	 that	utilize	objective	primary	outcome	measures.	
Subjective	cognitive	impairment	is	also	important	to	ensure	that	the	
treatment	 is	meaningful	and	 that	patients	comply	with	 trial	 require-
ments.	However,	some	patients	are	unaware	of	their	deficits	and	do	
not	 report	 them,	 but	 may	 nevertheless	 experience	 difficulties	 with	
retaining	normal	functioning	at	work	and	in	daily	life	due	to	their	cog-
nitive	 impairments.20	Given	 this,	 it	would	be	advisable	 to	enroll	 pa-
tients	that	present	with	both	(i)	subjective	cognitive	difficulties	and/
or	socio-	occupation	problems	and	(ii)	objectively	measured	cognitive	
deficits.	For	efficiency	purposes,	a	sequential	screening	process	may	
be	considered.	First,	a	large	number	of	patients	could	be	given	easy-	
to-	administer	subjective	measures	 (questionnaires)	 to	pre-	screen	for	
cognitive	 complaints	 and	 socio-	occupational	 problems.	 This	will	 aid	
recruitment	and	retaining	of	participants	in	the	trial.	Second,	patients	
with	self-	reported	cognitive	complaints	and/or	socio-	occupational	dif-
ficulties	can	then	be	assessed	with	an	objective	tool	(i.e.,	brief	neuro-
psychological	 test)	 to	substantiate	that	they	also	display	measurable	
cognitive	deficits	and	thus	ensure	indication	enrichment.
Several	self-	report	and	neuropsychological	measures	may	be	 im-
plemented	 in	 this	 screening	 process.	Two	 new	 screening	 tools	with	
4  |     MISKOWIAK et Al.
documented	 sensitivity	 to	 cognitive	 impairment	 in	 bipolar	 disorder	
may	 be	 particularly	 feasible:	 (i)	 the	 self-	report	 measure	 Cognitive	
Complaints	in	Bipolar	Disorder	Rating	Assessment	(COBRA),21	for	as-
sessment	of	subjective	impairment,	and	(ii)	the	brief	neuropsycholog-
ical	 tool	 Screen	 for	Cognitive	 Impairment	 in	Psychiatry	 (SCIP),22	 for	
detection	of	objective	cognitive	 impairment.	An	alternative	approach	
to	screen	for	objective	cognitive	impairment	is	to	use	two	single	neu-
ropsychological	tests	that	tap	into	different	cognitive	domains,	such	as	
verbal	memory	and	executive	function.16	The	COBRA	has	been	devel-
oped	for	bipolar	disorder21;	using	a	cut-	off	of	>14	on	this	scale—which	
indicates	moderate	to	severe	self-	reported	difficulties—provides	ade-
quate	specificity	(74%)	but	somewhat	suboptimal	sensitivity	(68%)	for	
objective	cognitive	impairments.	The	optimal	cut-	offs	on	the	SCIP	for	
cognitive	impairment	have	been	investigated	in	several	studies.18,23,24 
In	the	context	of	pre-	screening	patients	for	cognition	trials,	we	suggest	
a	SCIP	cut-	off	of	<75	(for	details,	see	section	3.2).
3.2 | What is a reasonable threshold for cognitive 
impairment?
There	 is	 no	 consensus	 definition	 of	 “clinically	 significant”	 cognitive	
impairment	 in	 terms	 of	 standard	 deviations	 (SDs)	 for	 neuropsycho-
logical	test	performance	from	the	mean	of	a	normative	group.25	These	
definitions	therefore	vary	across	studies	of	neuropsychiatric	patients,	
with	some	using	a	cut-	off	corresponding	to	performance	scores	≥2	SD	
below	the	normative	mean,	and	others	using	less	conservative	cut-	offs	
of	≥1.5	or	≥1	SD	under	the	norm.25-27	It	is	also	unclear	whether	such	
thresholds	 should	 be	 based	 on	 single	 or	 several	 neuropsychological	
tests.25	 Notably,	 it	 is	 relatively	 common	 that	 cognitively	 intact	 peo-
ple,	defined	by	their	overall	composite	score,	perform	1	SD	under	the	
norm	on	a	single	neuropsychological	test.25	It	thus	seems	necessary	to	
apply	such	a	cognitive	impairment	threshold	to	two	or	more	cognitive	
tests.	 In	 a	 secondary	 analysis	 of	 data	 from	 the	 erythropoietin	 (EPO)	
trials,	participants	with	a	score	of	≥1	SD	below	the	norm	on	at	 least	
two	cognitive	tests	had	substantially	greater	chances	of	treatment	ef-
ficacy	 than	 unimpaired	 individuals.15	Notably,	 this	 did	 not	 represent	
simple	regression	towards	the	mean,	since	such	influence	of	baseline	
deficits	was	not	observed	in	the	placebo	group.15	However,	application	
of	a	threshold	of	≥1	SD	for	cognitive	impairment	to	a	global	cognition	
measure	based	on	a	broad	neuropsychological	assessment	is	likely	to	
be	too	conservative,	since	only	12%-	40%	patients	display	global	 im-
pairments.6-8	It	would	therefore	be	advisable	to	employ	a	less	conserv-
ative	 threshold	on	 a	 global	 cognition	measure,	 such	 as	 performance	
≥0.5	SD	 below	 the	 norm.	 Indeed,	 it	 has	 been	 shown	 in	 a	 receiving	
operator	characteristic	(ROC)	analysis	of	the	SCIP	that	using	a	cut-	off	
of	 <75—corresponding	 to	 ≥0.5	SD	 under	 the	 mean	 of	 healthy	 age-	
matched	controls—provides	adequate	sensitivity	and	specificity	(81%	
and	76%,	respectively)	for	detection	of	cognitive	impairments	in	bipo-
lar	disorder.18	Nevertheless,	the	selection	of	a	cut-	off	should	be	based	
on	a	balance	between	the	desired	specificity	for	cognitive	impairment	
and	practical	 recruitment	considerations	 in	 the	 individual	 trial.	While	
a	high	cut-	off	optimizes	specificity	and	 increases	statistical	power,	 it	
limits	inclusion	of	trial	participants	and	generalizability	of	the	findings.
3.3 | Why is consideration of cognitive reserve 
important?
If	logistically	feasible,	it	may	be	worth	establishing	cognitive	impairment	
with	reference	to	patients’	premorbid	cognitive	reserve,	as	reflected	
by	 their	 premorbid	 IQ,	 educational	 level	 and	 occupational	 attain-
ment.28	Cognitive	reserve	reflects	the	capacity	of	the	brain	to	tolerate	
neuropathology,	 minimize	 symptom	manifestations	 and	 slow	 down	
the	clinical	presentation	of	neurocognitive	decline.29,30	Consideration	
of	cognitive	reserve	is	relevant	since	neuropsychological	tests	alone	
may	be	less	sensitive	to	cognitive	change	in	patients	with	substantial	
above-	normal	premorbid	function.	Useful	IQ	or	premorbid	IQ	tests	in-
clude	the	National	Adult	Reading	Test	(or	locally	equivalent	tests),	the	
Advanced	Clinical	Solutions	(ACS)	Test	of	Premorbid	Functioning,	the	
Wide	Range	Achievement	Reading	Recognition	Test	and	the	2-	subtest	
IQ	from	the	Wechsler	Abbreviated	Scale	of	Intelligence.	Educational	
attainment	may	be	a	suboptimal	measure	of	premorbid	cognitive	re-
serve	and	for	matching	patients	and	controls,	since	patients	with	bipo-
lar	disorder	tend	to	complete	fewer	years	of	education	than	controls	
despite	comparable	IQ	levels.31	Obtaining	estimates	of	premorbid	IQ	
would	also	enable	detection	of	participants	with	 intellectual	disabil-
ity	(i.e.,	IQ	<	70-	75)	whose	poor	cognitive	performance	is	unlikely	to	
represent	illness-	associated	impairment	and	thus	be	more	resistant	to	
cognitive-	enhancing	treatments.	Such	assessments	could	inform	deci-
sions	on	(i)	whether	individuals	with	remarkably	high	cognitive	reserve	
but	only	small	impairments	(in	comparison	with	norms)	should	be	al-
lowed	in	the	trial	and	(ii)	whether	individuals	with	very	low	cognitive	
reserve	(e.g.,	IQ	<	80)	should	be	excluded	as	in	recent	studies.13,32
3.4 | Which criteria should be used to select trial 
participants?
There	is	great	disparity	 in	the	inclusion	and	exclusion	criteria	across	
RCTs	targeting	cognition	in	bipolar	disorder.	The	task	force	therefore	
carefully	evaluated	inclusion	and	exclusion	criteria	for	cognition	trials,	
taking	into	account	study	validity,	generalizability,	chances	for	signal	
detection,	and	recruitment	feasibility.	In	addition	to	improving	indica-
tion	enrichment	by	screening	for	objective	cognitive	impairment,	the	
following	recommendations	may	also	significantly	aid	the	methodol-
ogy	of	future	trials.
A	particular	challenge	for	cognition	trials	in	bipolar	disorder	is	the	
influence	of	mania	and	depression	symptoms,	and	their	episodic	na-
ture,	on	cognitive	function.33	Recommendations	on	whether	or	not	to	
allow	for	mood	symptoms	depend	on	the	particular	study	aim	and	type	
of	treatment	under	investigation.	For	trials	with	cognition	as	a	primary	
outcome,	patients	should	generally	be	partially	remitted	or	euthymic,	
depending	on	the	profile	of	the	drug	effects.	Specifically,	trials	investi-
gating	candidate	treatments	with	no	known	efficacy	on	mood	should	
allow	for	subsyndromal	symptoms	in	the	interest	of	recruitment	fea-
sibility	and	generalizability	of	the	results,	since	persistent	subsyndro-
mal	symptoms	(particularly	of	depression)	are	common	in	periods	of	
mood	stability.	In	contrast,	trials	investigating	medications	with	well-	
documented	effects	on	mood	should	preferentially	include	euthymic	
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patients	 to	 rule	 out	 “pseudo-	specificity”	 (i.e.,	 nonspecific	 cognitive	
improvement	due	to	treatment-	related	decrease	in	mood	symptoms).	
We	propose	euthymia	defined	as	Hamilton	Depression	Rating	Scale	
(HDRS)	 or	 Montgomery–Åsberg	 Depression	 Rating	 Scale	 (MADRS)	
and	Young	Mania	Rating	Scale	(YMRS)	scores	≤7.	Some	studies	have	
included	prospective	verification	of	euthymia,	where	patients	are	mon-
itored	for	up	to	1	month	prior	to	assessment.34,35	If	such	an	approach	
is	 logistically	 feasible,	 it	 offers	 a	more	 rigorous	method	 of	 ensuring	
the	euthymic	period	 is	stable.	However,	 it	should	be	noted	that	 the	
proposed	distinction	in	inclusion	criteria	between	euthymic	and	partly	
remitted	patients	may	be	somewhat	artificial,	since	patients	who	are	
euthymic	at	 inclusion	may	develop	mood	symptoms	during	 the	 trial	
period.	Further,	euthymic	patients	 included	 in	a	study	of	drugs	with	
known	antidepressant	effects	could	run	a	higher	risk	of	switching	to	
mania	than	patients	with	subsyndromal	depressive	symptoms.	Finally,	
for	trials	with	mood	symptoms	as	the	primary	outcome	and	cognition	
as	 a	 secondary	outcome,	 patients	will	 be	 presenting	with	moderate	
to	severe	mood	symptoms.	In	these	trials,	potential	treatment-	related	
cognitive	improvement	can	provide	only	preliminary	evidence	for	ef-
ficacy	on	cognition	and	necessitates	replication	in	a	study	with	cogni-
tion	as	the	primary	outcome.
Concomitant	 medications	 are	 a	 confounder	 in	 cognition	 trials	
due	to	their	effects	on	cognition	but	must	be	allowed	for	ethical	and	
clinical	reasons	to	maintain	mood	stability	and	to	ensure	the	repre-
sentativeness	of	the	patient	sample	(and	thus	generalizability	of	the	
findings).	The	 cognitive	 side	 effects	 of	 commonly	 prescribed	med-
ications	 for	 mood	 symptoms	 and	 anxiety	 are	 not	 fully	 elucidated.	
Nevertheless,	benzodiazepines	as	well	as	some	antipsychotics,	mood	
stabilizers	and	antidepressants	have	documented	cognitive	side	ef-
fects,	 partially	 due	 to	 their	 anti-	histaminergic,	 anti-	dopaminergic,	
and	anticholinergic	actions.4,5	It	is	therefore	advisable	to	avoid	high	
doses	of	concomitant	antipsychotics	and	anticholinergic	medications	
whenever	 possible.	 Decreasing	 doses	 of	medication	 should	 never-
theless	be	traded	off	against	the	risk	of	relapse	of	mood	symptoms,	
which	may	invalidate	results	of	the	trial.	It	would	also	be	advisable	to	
taper	benzodiazepines	 to	a	maximum	dose	equivalent	 to	≤22.5	mg	
oxazepam	or	≤7.5	mg	diazepam	per	day	(cut-	offs	for	doses	with	es-
timated	limited	cognitive	side	effects)	and	to	restrict	use	of	benzo-
diazepine	and	other	hypnotics	for	at	least	6	hours	prior	to	cognitive	
testing.	Serum	lithium	dose	should	be	monitored	and	be	kept	within	
the	therapeutic	range	throughout	the	trial	to	avoid	confounding	cog-
nitive	side	effects	of	lithium	toxicity.	In	general,	patients	should	be	on	
stable	medication	for	at	least	2-	6	weeks	before	trial	start,	depending	
on	whether	 the	 treatment	 change	 is	merely	 a	 dose	 adjustment	 or	
commencement	of	a	new	treatment.	Concomitant	medication	should	
be	 carefully	 recorded	 and,	 if	 possible,	 kept	 stable	 throughout	 trial	
participation.	If	a	candidate	treatment	is	found	to	improve	cognition,	
post	hoc	analysis	should	include	adjustment	for	concomitant	medi-
cations	to	determine	whether	the	significant	effects	prevail	(and	are	
thus	 independent	 of	 non-	study	medication).	 Finally,	 electroconvul-
sive	therapy	(ECT)	in	the	past	6	months	should	be	an	exclusion	cri-
terion	since	cognitive	impairments	may	in	such	cases	be	ECT-	rather	
than	illness-	associated.
There	is	a	need	for	consensus	on	how	to	tackle	medical	and	psy-
chiatric	comorbidity	in	cognition	trials.	In	general,	patients	should	be	
excluded	if	they	have	a	history	of	moderate	or	more	severe	brain	injury,	
neurological	disease,	current	uncontrolled	thyroid	condition,	unstable	
medical	 illness,	 current	 or	 recent	 (i.e.,	 within	 the	 past	 1-	3	months)	
alcohol	 and	 substance	 use	 disorders,	 or	 intellectual	 disability,	 since	
these	are	likely	to	hamper	the	chances	of	treatment	efficacy	on	cog-
nition.	Patients	should	also	be	excluded	if	they	have	a	current	comor-
bid	diagnosis	of	attention	deficit	hyperactivity	disorder	verified	during	
the	diagnostic	screening	interview,	since	the	investigational	treatment	
aims	target	cognitive	deficits	associated	more	specifically	with	bipolar	
disorder.	Comorbid	 anxiety	 and	 sleep	disorders	may	exacerbate	pa-
tients’	cognitive	 impairment.	However,	 they	should	not	be	exclusion	
criteria	since	this	would	impede	recruitment	and	generalizability,	given	
the	high	comorbidity	between	bipolar	disorder	and	anxiety	disorders	
36	and	high	rates	of	circadian	rhythm	disturbance	and	abnormal	sleep	
in	bipolar	disorder.37	However,	careful	recording	of	anxiety	symptoms	
and	sleep	quality	during	the	trial	 is	advisable	as	this	enables	investi-
gation	of	their	potential	 influence	on	treatment	effects	on	cognition	
in	exploratory	post	hoc	analyses.	Finally,	patients	recruited	into	cog-
nition	trials	should	have	mastery	of	the	language	in	which	the	neuro-
psychological	tests	are	validated/administered,	as	this	is	necessary	for	
obtaining	valid	cognitive	assessments	during	the	trial.
3.5 | How should efficacy on cognition be assessed?
There	 is	 a	 lack	 of	 consensus	 on	 which	 cognition	 measures	 to	 de-
fine	as	primary	outcomes	and	on	a	priori	 hierarchy	between	cogni-
tion	measures	 in	most	 trials	 in	bipolar	disorder.1	 In	 some	 instances,	
the	choice	of	the	cognitive	outcome	measure	may	be	driven	by	the	
specific	 brain	or	 cognitive	mechanisms	 that	might	be	 targeted	by	 a	
particular	agent	or	 treatment	under	study.	For	example,	 if	an	agent	
is	proposed	to	act	on	a	neurotransmitter	or	neural	system	that	sub-
serves	 a	 specific	 cognitive	 ability,	 it	may	 be	 desirable	 to	 select	 the	
primary	cognitive	outcome	based	on	this	demonstrated	link	between	
brain and behavior.38,39	 In	other	 instances,	there	may	not	be	a	clear	
specific	cognitive	target	and	therefore	a	key	recommendation	is	to	se-
lect	one	primary	broad	cognitive	composite	score	spanning	sustained	
attention,	verbal	memory,	and	executive	functions	that	is	sensitive	to	
the	cognitive	deficits	 in	bipolar	disorder,	such	as	the	ISBD	-	Battery	
for	Assessment	of	Neurocognition	 (ISBD-	BANC)	composite10	or	the	
“speed	of	complex	cognitive	processing”	composite15,40 which are im-
plemented	in	completed	and	ongoing	cognition	trials	(ClinicalTrial.gov	
ID:	NCT01470781).15,16,40	Given	the	cognitive	heterogeneity	in	bipo-
lar	disorder,	a	broad	cognitive	composite	score	may—by	summarizing	
the	change	across	several	domains—be	a	more	robust	outcome	than	
a	single	cognition	test	as	it	can	pick	up	small	cumulative	treatment	ef-
fects	across	several	cognitive	domains.9	The	recommended	procedure	
for	deriving	 such	a	common	metric	 for	 cognition	 is	 to	calculate	 the	
composite	score	as	the	mean	of	the	individual	component	z-	scores	for	
attention,	memory,	and	executive	function	tests	standardized	against	
a	healthy	normative	sample	of	average	intelligence.	Ideally,	the	vari-
ous	individual	measures	would	have	been	co-	normed,	i.e.,	the	norms	
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would	have	been	collected	from	the	same	normative	population,	and	
demographic-	corrected	 norms	 (e.g.,	 age,	 IQ/education	 and	 gender)	
would	be	available.	Alternative	strategies	may	be	considered	if	there	
is	no	available	norm	group	for	the	particular	tests,	such	as	use	of	meta-	
norms,	or	calculating	z-	scores	by	referencing	the	scores	to	the	study	
baseline	or	control	group	performance.
The	use	of	a	specific	set	of	neuropsychological	 tests	for	the	pri-
mary	 cognition	 outcome	 across	 all	 future	 cognition	 trials	 would	
maximize	comparability	between	studies.	However,	 the	task	force	 is	
mindful	of	the	international	research	community	and	that	not	all	coun-
tries	have	the	exact	tests	of	the	ISBD-	BANC	or	the	“speed	of	complex	
cognitive	processing”	composites	available.	The	 task	 force	 therefore	
recommends	 that	 trials	match	 the	 neuropsychological	 tests	 in	 their	
primary	cognition	outcome	as	closely	as	possible	 to	the	tests	 in	 the	
ISBD-	BANC	or	“speed	of	complex	cognitive	processing”	composites.	
Broadly	equivalent	tests	probing	attention,	verbal	memory	and	exec-
utive	function	would	thus	be	adequate.	While	not	developed	for	bi-
polar	disorder,	the	MATRICS	Consensus	Cognitive	Battery	(MCCB)	is	
translated	into	>50	languages	and	normed	in	many	countries	and	it	has	
been	validated	in	bipolar	disorder	in	several	independent	samples.41-43 
Given	 that	 the	 ISBD-	BANC	 includes	 many	 of	 the	 MCCB	 subtests,	
there	 should	 be	 a	 reasonable	 ability	 for	 trials	 to	 include	most	 tests	
of	 the	 ISBD-	BANC.	A	degree	of	 flexibility	 is	 also	 advisable	 in	 cases	
where	prior	studies	have	shown	benefits	of	a	compound	on	specific	
cognitive	tests;	in	such	cases,	it	would	be	meaningful	to	include	these	
tests	in	the	primary	cognition	outcome	in	subsequent	replication	trials.	
Important	next	steps	that	are	prerequisites	for	developing	consensus	
on	a	specific	test	battery	would	be:	(i)	a	factor-	analytic	study	of	cogni-
tive	impairments	in	bipolar	disorder	based	on	existing	cognitive	data	
sets,	and	(ii)	validating	the	factor	structure	against	external	validators	
such	as	functional	capacity.
Individual	cognition	outcomes	of	interest	for	bipolar	disorder	and	
for	a	particular	candidate	intervention	should	be	included	as	second-
ary	outcomes	 (together	with	a	 functional	outcome/co-	primary	mea-
sure;	see	later).	For	example,	social	cognition	(such	as	facial	expression	
recognition)	may	be	a	clinically	meaningful	secondary	outcome,	given	
the	often	persistent	and	debilitating	social	cognition	deficits	in	bipolar	
disorder.44,45	Finally,	individual	cognitive	tests	comprising	the	primary	
composite	 cognitive	outcome	should	be	 specified	 separately	 as	 ter-
tiary	explorative	outcomes.	This	enables	exploratory	analyses	of	the	
profile	of	the	treatment	effects	to	assess	which	tests	(i)	respond	most	
to	the	particular	treatment	and/or	(ii)	show	greatest	sensitivity	to	treat-
ment	 in	particular	 subgroups.	Such	 insights	can	provide	hypothesis-	
generating	evidence	which—if	confirmed	in	additional	trials	with	these	
particular	measures	as	primary	outcomes—could	eventually	pave	the	
way	for	more	personalized	treatments	of	cognitive	impairments.
3.6 | What is a “clinically relevant” cognitive 
improvement?
The	 lack	of	consensus	on	what	defines	a	 “clinically	 relevant”	cogni-
tive	 change	 is	 problematic	 for	 two	 reasons.	 First,	 such	 information	
is	 critical	 for	 sample	 size	 estimations	 to	 ensure	 adequate	 statistical	
power	for	detection	of	efficacy	on	the	primary	outcome.	Second,	this	
information	is	relevant	for	extrapolating	the	clinical	importance	of	po-
tential	treatment	effects	on	cognition.	If	the	treatment	goal	were	to	
correct	 a	deficit,	we	would	anticipate	effect	 sizes	equivalent	 to	 the	
known	deficits.	However,	smaller	treatment	effects	may	also	be	clini-
cally	meaningful—such	as	an	 improvement	 that	 is	half-	way	 towards	
the	normal	function	in	healthy	age-	matched	individuals.46
The	available	evidence	so	far	indicates	that	it	 is	probably	unreal-
istic	 to	 expect	 large	 effect	 sizes	 for	 treatment	 effects	 on	 cognition.	
A	key	reason	is	the	well-	documented	learning	or	practice	effect	with	
repeated	testing	(i.e.,	nonspecific	improvement	across	all	participants),	
which	reduces	the	difference	in	cognitive	change	between	active	and	
control	groups	and	 thus	 the	magnitude	of	 the	 treatment	effects.	To	
optimize	 the	 signal	 to	noise	 ratio	 for	 cognitive	change,	 trials	 should	
implement	parallel	equivalent	 forms	of	 the	neuropsychological	 tests	
for	 the	 pre-	 and	 post-	treatment	 assessments	 if	 available.	 However,	
since	learning	effects	are	almost	impossible	to	eliminate,	it	is	of	criti-
cal	importance	to	estimate	the	“clinically	relevant”	effect	on	cognition	
with	 reference	 to	 the	 cognitive	 change	 in	 the	 control	 group	 rather	
than	baseline	performance.	Given	the	issue	of	learning	effects,	small	
to	medium	effect	sizes	for	between-	group	differential	change	in	cog-
nition	(such	as	Cohen’s	d	of	0.2-	0.4)	may	arguably	represent	clinically	
relevant	treatment	effects.	We	recommend	that	all	trials	also	include	
measures	 of	 socio-	occupational	 function	 so	 that	 the	 impact	 of	 im-
provement	in	cognition	on	day-	to-	day	functioning	can	be	assessed.
3.7 | How should functional implications be 
evaluated?
A	major	 criticism	 of	 cognition	 trials	 has	 been	 that	 it	 is	 unclear	 from	
change	 in	 neuropsychological	 performance	 alone	 whether	 the	 treat-
ments	actually	have	real-	life	benefits	for	the	patients	in	terms	of	work	
and	social	function.	It	is	therefore	critical	in	cognition	trials	to	gain	insight	
into	the	functional	implications	of	potential	treatment	efficacy	on	cogni-
tion.	 Indeed,	 the	Food	and	Drug	Administration	 (FDA)	stipulates	 that	
cognition	 trials	 in	schizophrenia	must	provide	evidence	 for	 functional	
benefits	 of	 cognitive	 improvement.47	 Given	 this	 legacy	 from	 schizo-
phrenia	research,	cognition	trials	in	bipolar	disorder	will	need	to	make	
decisions	about	how	to	define	their	key	secondary	(if	not	co-	primary)	
measure	of	functional	change.	Inclusion	of	a	functional	measure	would	
also	enable	assessment	of	the	potential	interaction	between	functional	
status	and	 the	cognition	benefits	of	an	 intervention,	which	would	be	
interesting	in	light	of	preliminary	evidence	for	greater	treatment-	related	
cognitive	improvement	in	high-	vs	low-	functioning	patients,48
Two	 promising	 existing	 tools	 are	 the	 observer-	based	 measure,	
the	Functional	Assessment	Short	Test	(FAST),49	and	the	performance-	
based	 test,	 the	 Brief	 University	 of	 California,	 San	 Diego	 (UCSD)	
Performance-	based	Skills	Assessment	(UPSA-	B).50	Both	tools	are	sen-
sitive	to	functional	impairments	in	bipolar	disorder,49,50	and	the	FAST	
has	shown	sensitivity	 to	 treatment	effects.13	The	FAST	assesses	as-
pects	of	everyday	functioning	through	self-	report	and	clinical	obser-
vations,	while	the	UPSA	is	a	performance-	based	measure	of	skills	(e.g.,	
handling	finances	and	planning	shopping)	associated	with	functional	
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outcomes.	However,	these	functional	measures	are	not	exempt	of	lim-
itations.	While	the	UPSA-	B	is	available	in	several	languages,	it	retains	
some	transcultural	problems.	A	more	general	limitation	of	both	mea-
sures	is	that	they	do	not	directly	assess	patients’	real-	world	function.	
New	virtual	reality	tools	are	therefore	being	developed,	including	the	
Virtual	 Reality	 Functional	 Capacity	Assessment	Tool	 (VRFCAT).	This	
tool	 presents	 participants	 with	 realistic	 simulated	 environments	 to	
recreate	daily	 living	activities	 (e.g.,	 cooking,	using	public	 transporta-
tion	and	food	shopping)	and	seems	to	be	a	valid	and	sensitive	assay	of	
functional	capacity.51	Taken	together,	the	FAST,	UPSA-	B	and	VRFCAT	
all	seem	adequate	measures	for	tracking	changes	in	functional	capac-
ity	associated	with	cognitive	improvement	in	bipolar	disorder,	although	
additional	validation	data	in	the	disorder	are	currently	a	research	prior-
ity.	Additional	“harder	measures”	of	functional	capacity,	such	as	occu-
pational	and/or	academic	achievement,	should	also	be	assessed	since	
some	measures	may	correlate	more	with	cognition	or	mood	symptoms	
than	with	real-	world	functioning.
3.8 | When should pre- and post- assessments be 
conducted?
The	 treatment	periods	 in	RCTs	 targeting	 cognition	 range	 from	1	 to	
21	weeks	but	are	most	commonly	between	6	and	12	weeks.1,16	Short	
study	durations	have	the	benefit	of	limiting	the	confounding	effects	
of	mood	 cycling,	whereas	 longer	 trial	 durations	may	be	more	 likely	
to	 produce	 robust	 and	 enduring	 efficacy	 on	 cognition	 and	 reduce	
potential	 practice	 effects.	 The	 optimal	 duration	 of	 a	 particular	 trial	
would	depend	on	 the	presumed	onset	of	efficacy	 for	 the	particular	
intervention	based	on	its	putative	mechanisms.	Specifically,	relatively	
pronounced	effects	may	be	seen	rapidly,	depending	on	the	agent.	For	
example,	a	single	dose	of	modafinil	was	recently	found	to	have	acute	
effects	on	some	aspects	of	cognition	in	remitted	major	depressive	dis-
order.52	However,	a	general	recommendation	would	be	to	administer	
pharmacological	 and	 other	 biological	 interventions	 for	 6-	12	weeks	
and	psychological	 interventions	 for	10-	21	weeks,	depending	on	 the	
specific	treatment	program	with	pre-	and	post-	treatment	assessments	
of	cognition	at	baseline	and	immediately	after	treatment	completion	
(primary	time	for	assessment	of	efficacy).	When	possible,	a	follow-	up	
assessment	after	3-	6	months	would	be	desirable.	This	recommenda-
tion	 is	based	on	 (i)	 the	most	common	practice	 in	RCTs	of	biological	
and	psychological	candidate	treatments	 in	mood	disorders	targeting	
mood	symptoms	or	cognitive	impairment	and	(ii)	the	assumption	that	
the	 functional	 implications	 of	 treatment-	related	 increase	 in	 neuro-
plasticity	 would	 begin	 to	 emerge	 after	 4-	6	weeks	 and	 presumably	
increase	 further	with	 continued	 treatment.53	 The	 follow-	up	 assess-
ment	3-	6	months	after	 treatment	completion	would	serve	to	deter-
mine	not	only	whether	potential	treatment-	related	cognitive	benefits	
persist	long-	term,	but	also	whether	they	translate	into	functional	im-
provements,	which	are	likely	to	occur	with	a	time	lag.	An	analog	is	the	
typical	delay	between	the	physical	healing	of	a	sprained	ankle	and	a	
person’s	 resumption	of	 habitual	 levels	 of	 daily	 activity	 and	physical	
exercise.	It	is	thus	likely	that	it	takes	time	for	objective	cognitive	im-
provement	to	translate	into	better	functioning	in	daily	life.	Preliminary	
evidence	 from	 recent	EPO	 trials	 supports	 this	notion.	Here	 the	ob-
served	correlation	between	EPO-	treated	patients’	objective	cognitive	
improvement	and	subjective	cognitive	change	in	daily	life	was	medi-
ated	by	change	in	depressive	symptoms	in	the	acute	treatment	phase	
but	was	direct	6	weeks	after	trial	completion.15
3.9 | How should “pseudospecificity” be addressed?
Lack	 of	 control	 for	 changes	 in	 mood	 symptoms	 in	 the	 analysis	 of	
treatment-	associated	 cognitive	 change	 (i.e.,	 the	 “pseudospecificity”	
issue)	is	generally	problematic	in	trials	of	cognition	in	bipolar	disorder	
as	some	patients	may	develop	mood	symptoms	during	the	trial	period.	
It	is	hence	important	to	(i)	adjust	the	analysis	of	treatment-	related	cog-
nitive	change	for	symptom	fluctuation	by	covarying	for	change	in	mood	
symptoms	from	baseline	to	post-	treatment	at	the	group	level	and/or	(ii)	
conduct	path	analysis,	which	can	provide	an	estimate	of	whether	the	
effects	on	cognition	were	direct	or	simply	mediated	through	symptom	
improvement.	 In	 trials	 aiming	 to	 improve	mood	 symptoms	 as	 a	 pri-
mary	goal	and	include	cognition	as	a	secondary	treatment	target,	such	
analyses	can	provide	valuable	hypothesis-	generating	evidence	for	an	
indication	for	cognitive	impairment	that	may	be	further	explored	in	a	
subsequent	 trial	with	cognition	as	 the	primary	outcome	 (as	exempli-
fied	by	the	vortioxetine	trials	in	unipolar	disorder54).	In	addition	to	the	
primary	intention-	to-	treat	(ITT)	strategy,	exploratory	post	hoc	analyses	
can	also	be	conducted	to	examine	whether	treatment	effects	differ	be-
tween	patients	who	remain	stable	throughout	the	study	and	patients	
with	emerging	mood	symptoms	during	the	trial.
3.10 | What are the methodological 
recommendations for specific classes of agents?
Some	 methodological	 considerations	 are	 tied	 to	 the	 properties	 of	
the	 particular	 candidate	 treatment	 under	 investigation,	 and	 there-
fore	differ	between	pro-	dopaminergic	drugs,	atypical	antipsychotics,	
anti-	inflammatory	 agents,	 and	 neuroprotective	 drugs.	 In	 particular,	
drug-	specific	 considerations	 include	 decisions	 about	 what	 clinical	
state	patients	should	be	 in,	which	secondary	cognition	outcomes	to	
select,	whether	 to	use	an	adjunctive	or	monotherapy	design,	which	
comparator	to	choose	(placebo	or	an	active	treatment	with	no	known	
effects	on	cognition),	and,	for	adjunctive	studies,	which	concomitant	
medication	to	allow.	Monotherapy	should	only	be	used	if	the	candi-
date	cognition	treatment	under	investigation	has	mood-	stabilizing	ef-
fects	for	ethical	reasons	and	to	ensure	generalizability	of	the	findings.	
Such	trials	would	necessitate	an	active	comparator	drug	with	mood-	
stabilizing	effects,	since	withholding	mood-	stabilizing	treatment	from	
patients	could	trigger	new	illness	episodes.
Pro-	dopaminergic	drugs	such	as	pramipexole	and	modafinil	should	
be	 investigated	 in	 an	 adjunctive	 design	 given	 some	 concern	 about	
potential	 risk	of	mania	 switch.55,56	 Such	 trials	 should	 ideally	 restrict	
recruitment	to	euthymic	patients,	given	the	antidepressant	effects	of	
these	 compounds,57,58	which	would	 confound	 the	 interpretation	 of	
potential	 cognitive	 benefits	 in	 symptomatic	 patients.	 Alternatively,	
they	 could	 include	depressed	patients	 in	 a	 head-	to-	head	 adjunctive	
8  |     MISKOWIAK et Al.
superiority	 design	with	 a	 comparator	without	 pro-	cognitive	 effects,	
although	euthymic	patients	are	better	 to	 rule	out	pseudospecificity.	
Preliminary	evidence	suggests	that	the	cognitive	benefits	of	pramipex-
ole	are	restricted	to	strictly	euthymic	patients.12	It	could	therefore	be	
hypothesized	that	the	cognitive	benefits	of	increasing	prefrontal	dopa-
mine	tonus	with	pro-	dopaminergic	drugs	may	be	confined	to	patients	
with	 relatively	 low	baseline	dopamine	 tonus	 (as	 in	euthymia).	Given	
the	drug	effects	on	dopaminergic	neurotransmission,	inclusion	of	a	re-
ward	processing	or	emotional	decision-	making	cognition	measure	as	
a	 secondary	 outcome	 could	 aid	mechanistic	 insight	 into	 the	 clinical	
effects	of	the	treatment,	as	illustrated	in	the	pramipexole	trial.59
Cognition	 trials	 investigating	 anti-	psychotic	 or	 antidepressant	
drugs	with	efficacy	on	depressive	symptoms,	such	as	lurasidone	and	
vortioxetine,	 should	 include	 euthymic	 patients	 to	 rule	 out	 pseudo-
specificity.	 Such	 trials	may	wish	 to	 include	 an	 emotional	 processing	
test	as	a	secondary	outcome	to	assess	the	mechanisms	of	treatment	
efficacy	 on	 depression.	 For	 antidepressants,	 the	 trial	 design	 should	
be	adjunctive	and	mood	state	carefully	monitored	as	antidepressant	
monotherapy	 is	 not	 usually	 recommended	 in	 bipolar	 disorder,	 given	
concern	about	potential	mania	switch	in	response	to	vortioxetine.60 In 
contrast,	trials	investigating	anti-	inflammatory	agents	or	neuroprotec-
tive	drugs	(such	as	EPO)	with	no	documented	effects	on	bipolar	de-
pression	would	arguably	benefit	from	expanding	the	inclusion	criteria	
to	partial	 remission	 (i.e.,	allowing	 for	more	subsyndromal	depressive	
symptoms)	in	the	interest	of	recruitment	feasibility	and	generalizability	
of	 the	 findings.	For	 the	 same	 reason,	 the	 trial	 design	 should	be	ad-
junctive	and	involve	a	placebo	control	arm.	These	recommendations	
(i.e.,	 inclusion	 of	 partially	 remitted	 patients	 and	 using	 an	 adjunctive	
design	with	a	control	group)	also	apply	to	psychological	interventions	
for	cognitive	impairment	such	as	cognitive	and	functional	remediation.
3.11 | How should statistical issues around missing 
data be handled?
Strategies	 for	 handling	missing	 data	 differ	 between	 cognition	 trials	
despite	the	general	recognition	that	intention-	to-	treat	(ITT)	analyses	
should	be	 implemented	to	prevent	bias	caused	by	participant	drop-
out.	 However,	 the	 definition	 of	 ITT	 is	 vague	 and	 involves	 several	
approaches	 for	 handling	missing	 data	 in	 longitudinal	 trials.	 Last	 ob-
servation	 carried	 forward	 (LOCF)	 is	 one	 approach	 that	 involves	 im-
putation	of	the	missing	values	with	the	last	observed	value,	assuming	
that	the	outcomes	would	be	unchanged	from	the	last	observed	value.	
Although	LOCF	minimizes	the	number	of	participants	eliminated	from	
the	analysis,	it	has	been	criticized	for	underestimating	the	variability	in	
the	data,	particularly	if	there	is	a	large	amount	of	missing	data.	More	
feasible	ways	to	handle	missing	data	with	repeated	assessments	are	
multiple	imputation	or	mixed	models,	which	are	more	robust	and	take	
account	of	missing	values,	including	whether	data	are	missing	at	ran-
dom,	and	inter-	individual	changes	over	time.	These	statistical	methods	
are	increasingly	used	in	clinical	research	because	of	their	availability	in	
many	statistical	software	packages.
In	cognition	trials,	there	will	often	be	only	two	cognition	data	points	
in	the	primary	analysis	(i.e.,	baseline	and	post-	treatment)	to	minimize	
learning	effects.	If	the	primary	outcome	is	cognitive	change	from	base-
line,	 inclusion	of	data	 from	patients	with	only	baseline	 assessments	
will	provide	very	 limited	 information	 in	 the	 statistical	model,	 adding	
only	 to	 the	estimation	of	 the	between-	subject	variance	 in	 the	data.	
The	results	of	the	analysis	will	therefore	be	highly	similar	to	those	of	
a	modified	ITT	analysis,	 in	which	data	are	analyzed	for	patients	with	
both	data	points.	However,	mixed	models	or	multiple	imputation	pro-
cedures	are	highly	 feasible	 for	 the	 (secondary)	analysis	of	 long-	term	
cognitive	change	that	includes	more	data	points.	Nevertheless,	there	
are	no	universal	standards,	as	the	most	appropriate	method	for	han-
dling	missing	data	depends	on	the	goals,	endpoints	and	context	of	the	
particular	trial.
4  | FUTURE PERSPECTIVES
4.1 | Need for insight into the neurobiological 
targets of cognitive enhancement
The	 FDA	 Critical	 Path	 Initiative	 has	 highlighted	 neuroimaging	 in	
human	populations	as	a	key	tool	to	accelerate	the	screening	and	selec-
tion	of	new	candidate	central	nervous	system	(CNS)	treatments.61	For	
cognition	trials,	assessment	of	neuroimaging	biomarkers	will	increase	
insight	into	the	neurobiology	of	cognitive	improvement	and	thereby	
lead	 to	 identification	of	 common	biomarkers	of	pro-	cognitive	 inter-
ventions.	 Specifically,	 the	 application	 of	 neuroimaging	 in	 cognition	
treatment	discovery	carries	the	potential	 to	 identify	early	change	 in	
key	neuronal	networks	that	predicts	subsequent	cognitive	 improve-
ment.	Detection	of	such	neuro-	circuitry	target	engagement	and	dose−
response	 findings	 could	 guide	 the	 development	 of	 new	mechanism	
compounds	 for	 cognitive	 impairment	 as	 a	 conceptually	 important	
middle	 step	between	 investigation	of	 such	 treatments	 in	preclinical	
models	and	large-	scale	clinical	phase	III	trials.	This	is	in	line	with	the	
National	Institutes	of	Health	(NIH)	statement	around	target	engage-
ment	 as	 a	 potential	 regulatory	 pathway.62	 Electrophysiological	 and	
psychophysiological	methods	may	also	aid	insight	into	the	neurobio-
logical	 underpinnings	 of	 cognitive	 impairments	 and	 neuronal	 target	
engagement.	In	particular,	quantitative	electroencephalography	(EEG)	
seems	to	provide	sensitive	biomarkers	for	cognitive	impairments	and	
treatment-	related	cognitive	change	in	neurological	disorders63,64 and 
would	be	interesting	to	include	in	trials	in	bipolar	disorder.
Emerging	evidence	points	to	aberrant	activity	in	the	dorsal	pre-
frontal	cortex	(PFC)	and	related	circuitries	as	well	as	failure	to	sup-
press	 default	 mode	 network	 (DMN)	 activity	 as	 common	 neuronal	
correlates	of	cognitive	 impairment	across	distinct	neuropsychiatric	
disorders.65-72	 In	 a	 series	 of	 randomized	 placebo-	controlled	 func-
tional	magnetic	 resonance	 imaging	 (fMRI)	 studies,	a	single	dose	of	
EPO	 and	 long-	term	 EPO	 treatment	 produced	 target	 engagement	
in	 the	 dorsal	 PFC	 and	DMN	 during	 strategic	 encoding	 and	work-
ing	memory	 across	 healthy	 individuals	 and	 patients	with	 affective	
disorders,	 and	 this	 activity	 change	 correlated	 with	 cognitive	 im-
provement.73-75	Meta-	analytic	 findings	also	point	 to	an	 increase	 in	
dorsal	 prefrontal	 activity	 as	 the	most	 reliable	 marker	 of	 cognitive	
improvement	 in	response	to	cognitive	remediation	interventions	in	
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schizophrenia.76	There	is	also	emerging	evidence	for	structural	hip-
pocampal	volume	increase	as	a	key	neurobiological	target	for	cogni-
tion	treatments.	Indeed,	structural	MRI	assessments	of	patients	with	
affective	disorders	in	the	RCTs	of	long-	term	EPO	vs	saline	treatment	
revealed	 increased	 subregional	 volume	 in	 the	 left	 hippocampus	 in	
EPO-	treated	 patients,	 which	 correlated	 with	 EPO-	related	 verbal	
memory	improvement.77	Similarly,	MRI	assessment	of	an	RCT	of	cog-
nitive	 remediation	 in	 schizophrenia	 showed	 treatment-	associated	
preservation	of	 left	hippocampal	 gray	matter	volume	over	2	years,	
which	 mediated	 the	 improvement	 of	 cognition.78	 Taken	 together,	
this	emerging	neuroimaging	evidence	points	to	PFC	and	DMN	tar-
get	engagement	as	well	as	hippocampal	volume	increase	as	potential	
biomarkers	for	pro-	cognitive	effects	of	distinct	pharmacological	and	
psychological	 interventions	 across	 several	 psychiatric	 disorders—
possibilities	that	warrant	investigation	in	future	trials.
Finally,	it	would	also	be	of	key	interest	to	include	assessments	of	
potential	blood-	based	biomarkers	 for	 cognitive	 improvements	 in	 fu-
ture	trials,	given	emerging	evidence	for	a	putative	role	of	inflammation	
and	oxidative	 stress	 in	 patients’	 cognitive	 deficits.79	 Specifically,	 as-
sessments	of	changes	in	such	biomarkers	early	in	the	course	of	treat-
ment	 can	 lead	 to	 identification	 of	markers	 that	 predict	 subsequent	
treatment	efficacy	on	cognition.
TABLE  1 Quick	guide	with	a	summary	of	the	International	
Society	for	Bipolar	Disorders	(ISBD)	Targeting	Cognition	Task	Force	
recommendations
Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 
Cognition Task Force: quick guide
How	can	we	enrich	trials	with	cognitively	impaired	patients?
Assess	subjective	cognitive	difficulties	and	functional	capacity
Screen	for	cognitive	impairment	with	a	brief,	feasible	neuropsycho-
logical	test	battery
Two	new	screening	tools	for	cognitive	impairment	may	be	
particularly	feasible:	the	COBRA	(self-	report	measure)	and	the	
SCIP	(brief	neuropsychological	test	battery)
What	is	a	feasible	threshold	for	cognitive	impairment?
≥	0.5	SD	below	the	normative	mean	on	a	short	neuropsychological	
screening	test	or,	alternatively,	≥1	SD	below	the	mean	on	at	least	
two	single	neuropsychological	tests
If	logistically	feasible,	cognitive	impairment	may	be	established	with	
reference	to	general	IQ
Which	criteria	should	be	used	to	select	trial	participants?
Generally	include	partially	or	fully	remitted	patients	in	trials	where	
cognition	is	the	primary	outcome	to	minimize	“pseudospecificity”	issues
Exclude	patients	with	a	history	of	moderate	or	severe	brain	injury,	
neurological	disease,	current	uncontrolled	thyroid	condition,	
unstable	medical	illness,	current	or	recent	alcohol	and	substance	use	
disorders,	intellectual	disability,	or	ECT	within	the	past	6	months
Allow	concomitant	medications.	These	should	be	carefully	recorded	
and,	if	possible,	kept	stable
In	possible,	disallow	certain	medications	(high-	dose	antipsychotics	
and	anticholinergic	medications)
Taper	benzodiazepines	to	a	maximum	dose	equivalent	to	22.5	mg	
oxazepam/7.5	mg	diazepam	per	day	and	restrict	use	of	benzodiaz-
epine	and	other	hypnotics	6	hours	prior	to	cognitive	testing
Keep	serum	lithium	within	the	therapeutic	range
How	should	efficacy	on	cognition	be	assessed?
In	general,	select	a	broad	cognitive	composite	score	spanning	
sustained	attention,	verbal	memory,	and	executive	functions	as	
the	primary	outcome
Use	tests	that	are	broadly	equivalent	to	those	included	in	the	
ISBD-	BANC
Select	key	cognitive	tests	of	interest	and	a	functional	measure	as	
secondary	outcomes
What	is	a	“clinically	relevant”	cognitive	improvement?
Since	learning	effects	are	almost	impossible	to	eliminate,	a	
“clinically	relevant”	effect	on	cognition	should	be	estimated	with	
reference	to	the	cognitive	change	in	the	control	group
Given	the	issue	with	learning	effects	(which	reduce	the	difference	
between	the	active	and	control	groups),	small	to	medium	effect	
sizes	for	treatment	effects	may	be	considered	clinically	meaningful
How	should	functional	implications	be	evaluated?
The	FAST,	UPSA-	B	and	VRFCAT	are	among	the	best	measures	to	
date	for	tracking	changes	in	functional	capacity	associated	with	
cognitive	improvement	in	bipolar	disorder
When	should	pre-	and	post-	assessments	be	conducted?
In	general,	administer	biological	interventions	for	6-	12	weeks	and	
psychological	interventions	for	10-	21	weeks	with	pre-	and	
post-	treatment	assessments	of	cognition	at	baseline	and	
immediately	after	treatment	completion.	If	feasible,	perform	
follow-	up	assessments	after	3-	6	months
Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 
Cognition Task Force: quick guide
How	should	“pseudospecificity”	be	addressed?
Adjust	the	statistical	analysis	of	cognitive	change	for	symptom	
fluctuation	and	conduct	path	analysis
What	are	the	methodological	recommendations	for	specific	classes	of	
agents?
Monotherapy	should	only	be	used	if	the	candidate	treatment	has	
mood-	stabilizing	effects	for	ethical	reasons	and	to	ensure	
generalizability.	Use	an	active	comparator	drug	with	mood-	
stabilizing	effects.
Cognition	trials	investigating	anti-	psychotic,	pro-	dopaminergic	or	
antidepressant	drugs	with	efficacy	on	depressive	symptoms	
should	ideally	include	euthymic	patients	to	rule	out	pseudospeci-
ficity.	Alternatively,	they	can	include	depressed	patients	in	a	
head-	to-	head	adjunctive	superiority	design	with	a	comparator	
without	pro-	cognitive	effects
Trials	investigating	anti-	inflammatory	or	neuroprotective	drugs	with	
limited	effects	on	mood	would	benefit	from	expanding	the	
inclusion	criteria	to	partial	remission	in	the	interest	of	recruitment	
feasibility	and	generalizability.	Use	an	adjunctive	study	design	with	
a	placebo	control
How	should	statistical	issues	around	missing	data	be	handled?
Intention-	to-	treat	analyses	should	be	implemented	to	prevent	bias	
caused	by	dropout
Feasible	ways	to	handle	missing	data	with	repeated	assessments	
after	treatment	start	are	multiple	imputation	or	mixed	models
COBRA,	 Cognitive	 Complaints	 in	 Bipolar	 Disorder	 Rating	 Assessment;	
ECT,	electroconvulsive	therapy;	FAST,	Functional	Assessment	Short	Test;	
SCIP,	Screen	for	Cognitive	Impairment	in	Psychiatry;	SD,	standard	devia-
tion;	UPSA-	B,	Brief	UCSD	Performance-	based	Skills	Assessment;	VRFCAT,	
Virtual	Reality	Functional	Capacity	Assessment	Tool.
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4.2 | Targeting of treatments according to patients’ 
illness stage
There	is	increasing	evidence	for	clinical	progression	in	bipolar	disor-
der80	 and	growing	consensus	 that	bipolar	disorder	 involves	 “clinical	
staging,”	a	progression	from	prodromal	(at-	risk)	stages	to	more	severe	
and	resistant	presentations.81,82	In	line	with	the	staging	model,	inter-
ventions	seem	to	have	differential	efficacy	depending	on	patients’	ill-
ness	stage	and	interventions	should	therefore	be	tied	to	the	particular	
illness	stage.81,82	Extrapolating	from	this,	inclusion	of	a	heterogeneous	
group	of	patients	 at	 various	 stages	of	 their	 illness	 could	potentially	
preclude	treatment	efficacy	on	cognition.	This	raises	questions	about	
whether	future	cognition	trials	should	stratify	patients	for	their	illness	
stage	and,	if	so,	which	stages	to	target	with	cognition	treatment.
In	 the	 EPO	 trials,	 there	 was	 a	 small	 but	 significant	 increase	 in	
patients’	 chances	 of	 achieving	 treatment	 efficacy	 on	 cognition	with	
greater	illness	chronicity	(16%	for	every	year	of	illness).14	If	the	finding	
is	generalizable,	cognition	treatments	may	be	more	beneficial	at	later	
illness	stages	that	are	accompanied	by	greater	cognitive	and	functional	
disability.	On	the	other	hand,	cognitive	impairment	at	later	stages	may	
be	more	treatment-	resistant	and	be	accompanied	by	greater	functional	
disability,	which	could	have	been	prevented	with	an	early	intervention.	
Indeed,	preliminary	evidence	from	a	schizophrenia	trial	suggests	that	
cognitive	 remediation	 is	more	effective	 in	younger,	 less	 functionally	
impaired	patients	who	use	less	antipsychotic	medication.83	Given	the	
paucity	 of	 evidence	 for	 stage-	specific	 effects	 on	 treatment	 efficacy	
on	cognition	in	bipolar	disorder,	this	question	should	be	addressed	in	
future	cognition	trials.
4.3 | Potential for a multimodal treatment approach
The	 combination	 of	 pharmacological	 and	 non-	pharmacological	 (i.e.,	
psychological	 or	 neurostimulation)	 interventions	 is	 likely	 to	 pro-
duce	 synergistic	 effects	 on	 brain	 function	 that	 translate	 into	 more	
robust	 efficacy	 on	 cognition	 than	 either	 treatment	 modality	 alone.	
Importantly,	 the	 translation	of	 treatment-	related	cognitive	 improve-
ment	 into	 greater	 functional	 capacity	 in	 chronically	 ill	 patients	may	
be	more	difficult	due	to	fewer	environmental	opportunities	to	apply	
regained	cognitive	skills.	In	this	respect,	it	may	be	necessary	in	chroni-
cally	ill	patients	to	apply	a	multi-	modality	approach.	There	is	currently	
a	paucity	of	evidence	for	synergistic	effects	of	multimodal	interven-
tions.	A	recent	preclinical	study	revealed	that	the	EPO-	associated	in-
crease	in	hippocampal	pyramidal	neurons	and	oligodendrocytes	was	
only	 maintained	 long-	term	 (≥6	months)	 in	 mice	 that	 also	 received	
continuous	cognitive	challenges.83	This	finding	is	consistent	with	the	
demonstration	 in	a	cognition	 trial	 in	unipolar	depression	 that	work-
ing	patients	displayed	greater	cognitive	benefits	of	vortioxetine	than	
those	who	were	unemployed.48	Taken	 together,	 these	observations	
are	 suggestive	of	 stronger	 treatment	effects	on	neuroplasticity	 and	
cognition	in	individuals	who	receive	continuous	cognitive	challenges.	
Multimodal	 treatment	approaches	should	therefore	be	considered	a	
key	 next	 step	 for	 trials	 that	 demonstrate	 cognitive	 improvement	 in	
response	to	unimodal	interventions.
5  | CONCLUSION
This	guidance	paper	 from	the	 ISBD	Targeting	Cognition	Task	Force	
provides	the	first	broad	consensus-	based	recommendations	for	future	
cognition	 trials	 in	bipolar	disorder,	which	may	help	overcome	some	
of	the	methodological	challenges	in	the	field.	The	recommendations	
are	 summarized	 in	Table	1.	Key	 recommendations	 are	 to	enrich	 tri-
als	with	cognitively	impaired	patients	by	screening	them	with	a	brief	
neuropsychological	test	battery,	to	generally	select	a	broad	cognitive	
composite	 score	 as	 the	 primary	 outcome	 and	 a	 functional	measure	
and	 key	 cognitive	 tests	 as	 secondary	outcomes,	 to	 include	partially	
or	fully	remitted	patients,	to	exclude	patients	with	current	substance	
or	alcohol	use	disorder,	to	disallow	certain	non-	study	medications	if	
possible	and	to	keep	all	other	concomitant	medication	stable.	While	
the	 ideal	design	will	vary	to	some	degree	depending	on	the	mecha-
nism	 being	 targeted	 and	 the	 hypothesized	 onset	 of	 effects,	 most	
recommendations	 are	 generally	 applicable	 for	 cognition	 trials	 in	 bi-
polar	 disorder.	 Following	 these	 recommendations	 will	 increase	 the	
internal	 validity	 of	 cognition	 trials	 by	 limiting	 confounding	 factors	
and	 the	external	validity	by	ensuring	generalizability	of	 the	 findings	
and	assessment	of	 their	 translation	 to	 real-	world	outcomes.	Finally,	
neuroimaging	 and	 electrophysiological	 assessments	 in	 future	 trials	
may	 identify	 the	 neurobiological	 targets	 for	 pro-	cognitive	 interven-
tions	 that	 can	aid	 future	drug	discovery	 strategies.	 Studies	 are	 also	
warranted	to	explore	the	potential	synergistic	effects	of	multimodal	
treatment	 approaches.	 Implementing	 the	 recommendations	 is	 likely	
to	 advance	our	 understanding	of	which	 cognition	 treatments	work,	
for	whom	and	why.	Specifically,	optimizing	the	trial	design	and	meth-
odology	 across	 trials	 so	 findings	 become	more	 replicable	 and	 com-
parable	will	 advance	 the	understanding	of	which	 treatments	do—or	
do	not—improve	cognition.	While	 the	 field	 is	 still	 in	 its	 infancy,	 the	
assessment	 of	whether	 cognition	 treatments	 should	 be	 targeted	 to	
particular	 illness	stages	will	clarify	 for	whom	these	treatments	have	
particular	benefits.	Finally,	neuroimaging	and	neurophysiological	as-
sessments	will	clarify	why	certain	treatments	work	by	elucidating	their	
neurobiological	mechanisms.
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